4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-20-049430
Chief Financial Officer sold 12,000 shares at an average $92.26 ($1,107,068)
- Chief Financial Officer acquired 12,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| TOMSICEK MICHAEL JOHN Chief Financial Officer | 2020-09-01 | Option exercise | +12,000 | $17.75 | $213,000 | 12,410 | D |
| TOMSICEK MICHAEL JOHN Chief Financial Officer | 2020-09-01 | Sale | −2,800 | $91.39 | $255,892 | 9,610 | D |
| TOMSICEK MICHAEL JOHN Chief Financial Officer | 2020-09-01 | Sale | −6,400 | $92.23 | $590,272 | 3,210 | D |
| TOMSICEK MICHAEL JOHN Chief Financial Officer | 2020-09-01 | Sale | −2,800 | $93.18 | $260,904 | 410 | D |
| Derivatives | |||||||
| TOMSICEK MICHAEL JOHN Chief Financial Officer | 2020-09-01 | Option exercise · Stock Option (Right to Buy) | −12,000 | 156,000 | D | ||
| Open-market sales · 12,000 sh · avg $92.26 · $1,107,068 | |||||||
Loading xslF345X03/doc4.xml…